An 8-year-old boy is undergoing treatment for low-grade glioma. The oncologist plans to add a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis. Which of the following biologic agents would be selected for this purpose?